Document is current
Any future updates will be listed below
-
Authors
Audo, Isabelle https://orcid.org/0000-0003-0698-5309
Barale, Pierre-Olivier
Devisme, Céline
Mohand-Said, Saddek
Meunier, Isabelle
Smirnov, Vasily M.
Dhaenens, Claire-Marie
Andrieu, Camille
Zeitz, Christina https://orcid.org/0000-0002-3510-1712
Pagot, Chloé
Barbier, Pascaline
Tindel, Malka
Chapon, Perrine
Sahel, Jose-Alain https://orcid.org/0000-0002-4831-1153
-
Funding
Funding for this research was provided by:
Novartis SAS France funded the study
- License Information
-
More Information
Article History
Received: 19 February 2024
Revised: 27 January 2025
Accepted: 5 February 2025
First Online: 14 March 2025
Competing interests
: The authors report no conflicts of interest, except for JAS who reports holding stock options in GenSight Biologics, Sparing Vision, Prophesee, Chronolife, Tilak Healthcare, VegaVect Inc., Avista, Tenpoint, SharpEye. He also reports paid or unpaid involvement in GenSight Biologics, SparingVision, Avista, Fondation Voir & Entendre, Foundation Fighting Blindness, Gilbert Foundation and Foundation Fighting Blindness.
